Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011 (2011), Article ID 247467, 9 pages
http://dx.doi.org/10.4061/2011/247467
Review Article

Lipid-Mediated Oxidative Stress and Inflammation in the Pathogenesis of Parkinson's Disease

1Department of Entomology/Center for Molecular Neurobiology, The Ohio State University, Columbus, OH 43210, USA
2Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH 43210, USA

Received 3 October 2010; Accepted 10 January 2011

Academic Editor: Carlos Barcia

Copyright © 2011 Tahira Farooqui and Akhlaq A. Farooqui. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. F. Beal, “Mitochondrial dysfunction in neurodegenerative diseases,” Biochimica et Biophysica Acta, vol. 1366, no. 1-2, pp. 211–223, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Jenner and C. W. Olanow, “The pathogenesis of cell death in Parkinson's disease,” Neurology, vol. 66, no. 10, supplement 4, pp. S24–S36, 2006. View at Google Scholar · View at Scopus
  3. M. J. Farrer, K. Haugarvoll, O. A. Ross et al., “Genomewide association, Parkinson disease, and PARK10,” American Journal of Human Genetics, vol. 78, no. 6, pp. 1084–1088, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. C. B. Lücking, A. Dürr, V. Bonifati et al., “Association between early-onset Parkinson's disease and mutations in the parkin gene,” New England Journal of Medicine, vol. 342, no. 21, pp. 1560–1567, 2000. View at Publisher · View at Google Scholar · View at PubMed
  5. A. A. Farooqui, Neurochemical Aspects of Neuroinflammation in Brain in Molecular Aspects of Neurodegeneration and Neuroprotection, Bentham Science, Oak Park, Ill, USA, 2010, A. A. Farooqui and T. Farooqui, Eds.
  6. C. Wang, L. Liu, L. Zhang, Y. Peng, and F. Zhou, “Redox reactions of the α-synuclein-Cu2+ complex and their effects on neuronal cell viability,” Biochemistry, vol. 49, no. 37, pp. 8134–8142, 2010. View at Publisher · View at Google Scholar · View at PubMed
  7. B. Halliwell, “Oxidative stress and neurodegeneration: where are we now?” Journal of Neurochemistry, vol. 97, no. 6, pp. 1634–1658, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. G. Y. Sun, L. A. Horrocks, and A. A. Farooqui, “The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases,” Journal of Neurochemistry, vol. 103, no. 1, pp. 1–16, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. A. Farooqui, W. Y. Ong, and L. A. Horrocks, Neurochemical Aspects of Excitotoxicity, Springer, New York, NY, USA, 2008.
  10. A. A. Farooqui and L. A. Horrocks, Glycerophospholipids in Brain, Springer, New York, NY, USA, 2007.
  11. M. Valko, H. Morris, and M. T. D. Cronin, “Metals, toxicity and oxidative stress,” Current Medicinal Chemistry, vol. 12, no. 10, pp. 1161–1208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. A. A. Farooqui, Neurochemical Aspects of Neurotraumatic and Neurodegenerative Disease, Springer, New York, NY, USA, 2010.
  13. J. D. Fernstrom, “Effects of dietary polyunsaturated fatty acids on neuronal function,” Lipids, vol. 34, no. 2, pp. 161–169, 1999. View at Google Scholar · View at Scopus
  14. A. Buisson, N. Lakhmeche, C. Verrecchia, M. Plotkine, and R. G. Boulu, “Nitric oxide: an endogenous anticonvulsant substance,” NeuroReport, vol. 4, no. 4, pp. 444–446, 1993. View at Google Scholar · View at Scopus
  15. A. M. Jenkinson, A. R. Collins, S. J. Duthie, K. W. J. Wahle, and G. G. Duthie, “The effect of increased intakes of polyunsaturated fatty acids and vitamin E on DNA damage in human lymphocytes,” FASEB Journal, vol. 13, no. 15, pp. 2138–2142, 1999. View at Google Scholar
  16. N. Shibata and M. Kobayashi, “The role for oxidative stress in neurodegenerative diseases,” Brain and Nerve, vol. 60, no. 2, pp. 157–170, 2008. View at Google Scholar · View at Scopus
  17. S. A. Lipton, Z. Gu, and T. Nakamura, “Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders,” International Review of Neurobiology, vol. 82, pp. 1–27, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. T. Nakamura and S. A. Lipton, “Emerging roles of S-nitrosylation in protein misfolding and neurodegenerative diseases,” Antioxidants and Redox Signaling, vol. 10, no. 1, pp. 87–101, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. Ebadi and S. K. Sharma, “Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease,” Antioxidants and Redox Signaling, vol. 5, no. 3, pp. 319–335, 2003. View at Google Scholar · View at Scopus
  20. D. M. Branco, D. M. Arduino, A. R. Esteves, D. F. Silva, S. M. Cardoso, and C. R. Oliveira, “Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis,” Frontiers in Aging Neuroscience, vol. 2, article 17, 2010. View at Google Scholar
  21. A. Atlante, P. Calissano, A. Bobba, A. Azzariti, E. Marra, and S. Passarella, “Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death,” Journal of Biological Chemistry, vol. 275, no. 47, pp. 37159–37166, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. M. A. Dronne, E. Grenier, T. Dumont, M. Hommel, and J. P. Boissel, “Role of astrocytes in grey matter during stroke: a modelling approach,” Brain Research, vol. 1138, no. 1, pp. 231–242, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. F. H. Khan, T. Sen, A. K. Maiti, S. Jana, U. Chatterjee, and S. Chakrabarti, “Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease,” Biochimica et Biophysica Acta, vol. 1741, no. 1-2, pp. 65–74, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. M. Bisaglia, M. E. Soriano, I. Arduini, S. Mammi, and L. Bubacco, “Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease,” Biochimica et Biophysica Acta, vol. 1802, no. 9, pp. 699–706, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. P. Klivenyi, M. F. Beal, R. J. Ferrante et al., “Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity,” Journal of Neurochemistry, vol. 71, no. 6, pp. 2634–2637, 1998. View at Google Scholar · View at Scopus
  26. T. P. Singer, N. Castagnoli Jr., R. R. Ramsay, and A. J. Trevor, “Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” Journal of Neurochemistry, vol. 49, no. 1, pp. 1–8, 1987. View at Google Scholar · View at Scopus
  27. M. Tariq, H. A. Khan, K. A. Moutaery, and S. A. Deeb, “Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents,” Brain Research Bulletin, vol. 54, no. 1, pp. 77–82, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Yoshinaga, Y. Yasuda, T. Murayama, and Y. Nomura, “Possible involvement of cytosolic phospholipase A2 in cell death induced by 1-methyl-4-phenylpyridinium ion, a dopaminergic neurotoxin, in GH3 cells,” Brain Research, vol. 855, no. 2, pp. 244–251, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Feng, D. Li, P. C. W. Fung, Z. Pei, D. B. Ramsden, and S. L. Ho, “COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice,” NeuroReport, vol. 14, no. 15, pp. 1927–1929, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Teismann, M. Vila, D. K. Choi et al., “COX-2 and neurodegeneration in Parkinson's disease,” Annals of the New York Academy of Sciences, vol. 991, pp. 272–277, 2003. View at Google Scholar · View at Scopus
  31. P. L. Wood, Neuroinflammation: Mechanisms and Managements, Humana Press, Totowa, NJ, USA, 1998.
  32. R. C. S. Seet, C. Y. J. Lee, E. C. H. Lim et al., “Oxidative damage in Parkinson disease: measurement using accurate biomarkers,” Free Radical Biology and Medicine, vol. 48, no. 4, pp. 560–566, 2010. View at Publisher · View at Google Scholar · View at PubMed
  33. H. Büeler, “Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease,” Experimental Neurology, vol. 218, no. 2, pp. 235–246, 2009. View at Publisher · View at Google Scholar · View at PubMed
  34. K. Beyer, “Mechanistic aspects of Parkinson's disease: α-synuclein and the biomembrane,” Cell Biochemistry and Biophysics, vol. 47, no. 2, pp. 285–299, 2007. View at Publisher · View at Google Scholar
  35. A. Ghosh, A. Roy, X. Liu et al., “Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, pp. 18754–18759, 2007. View at Publisher · View at Google Scholar · View at PubMed
  36. M. Sawada, K. Imamura, and T. Nagatsu, “Role of cytokines in inflammatory process in Parkinson's disease,” Journal of Neural Transmission, Supplement, no. 70, pp. 373–381, 2006. View at Google Scholar
  37. T. Nagatsu and M. Sawada, “Inflammatory process in Parkinson's disease: role for cytokines,” Current Pharmaceutical Design, vol. 11, no. 8, pp. 999–1016, 2005. View at Publisher · View at Google Scholar
  38. T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari, “Changes in cytokines and neurotrophins in Parkinson's disease,” Journal of Neural Transmission, Supplement, no. 60, pp. 277–290, 2000. View at Google Scholar
  39. V. Calabrese, C. Cornelius, E. Rizzarelli, J. B. Owen, A. T. Dinkova-Kostova, and D. A. Butterfield, “Nitric oxide in cell survival: a janus molecule,” Antioxidants & Redox Signaling, vol. 11, no. 11, pp. 2717–2739, 2009. View at Google Scholar
  40. T. Nakamura and S. A. Lipton, “S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases,” Antioxidants and Redox Signaling. In press.
  41. A. H. K. Tsang and K. K. K. Chung, “Oxidative and nitrosative stress in Parkinson's disease,” Biochimica et Biophysica Acta, vol. 1792, no. 7, pp. 643–650, 2009. View at Publisher · View at Google Scholar · View at PubMed
  42. K. K. K. Chung, B. Thomas, X. Li et al., “S-nitrosylation of parkin regulates ubiquitination and compromises Parkin's protective function,” Science, vol. 304, no. 5675, pp. 1328–1331, 2004. View at Publisher · View at Google Scholar · View at PubMed
  43. J. Correale and A. Villa, “The neuroprotective role of inflammation in nervous system Injuries,” Journal of Neurology, vol. 251, no. 11, pp. 1304–1316, 2004. View at Publisher · View at Google Scholar · View at PubMed
  44. A. A. Farooqui, L. A. Horrocks, and T. Farooqui, “Modulation of inflammation in brain: a matter of fat,” Journal of Neurochemistry, vol. 101, no. 3, pp. 577–599, 2007. View at Publisher · View at Google Scholar · View at PubMed
  45. E. C. Hirsch and S. Hunot, “Neuroinflammation in Parkinson's disease: a target for neuroprotection?” The Lancet Neurology, vol. 8, no. 4, pp. 382–397, 2009. View at Publisher · View at Google Scholar
  46. C. M. Long-Smith, A. M. Sullivan, and Y. M. Nolan, “The influence of microglia on the pathogenesis of Parkinson's disease,” Progress in Neurobiology, vol. 89, no. 3, pp. 277–287, 2009. View at Publisher · View at Google Scholar · View at PubMed
  47. M. G. Tansey and M. S. Goldberg, “Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention,” Neurobiology of Disease, vol. 37, no. 3, pp. 510–518, 2010. View at Publisher · View at Google Scholar · View at PubMed
  48. C. N. Serhan and J. Savill, “Resolution of inflammation: the beginning programs the end,” Nature Immunology, vol. 6, no. 12, pp. 1191–1197, 2005. View at Publisher · View at Google Scholar · View at PubMed
  49. A. A. Farooqui, L. A. Horrocks, and T. Farooqui, “Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide,” Journal of Neuroscience Research, vol. 85, no. 9, pp. 1834–1850, 2007. View at Publisher · View at Google Scholar · View at PubMed
  50. S. Amor, F. Puentes, D. Baker, and P. van der Valk, “Inflammation in neurodegenerative diseases,” Immunology, vol. 129, no. 2, pp. 154–169, 2010. View at Publisher · View at Google Scholar · View at PubMed
  51. C. J. Wilson, C. E. Finch, and H. J. Cohen, “Cytokines and cognition—the case for a head-to-toe inflammatory paradigm,” Journal of the American Geriatrics Society, vol. 50, no. 12, pp. 2041–2056, 2002. View at Publisher · View at Google Scholar
  52. Z. Xing, J. Gauldie, G. Cox et al., “IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses,” Journal of Clinical Investigation, vol. 101, no. 2, pp. 311–320, 1998. View at Google Scholar
  53. D. Sulzer, J. Bogulavsky, K. E. Larsen et al., “Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 11869–11874, 2000. View at Publisher · View at Google Scholar · View at PubMed
  54. I. Paris, J. Lozano, C. Perez-Pastene, P. Muñoz, and J. Segura-Aguilar, “Molecular and neurochemical mechanisms in PD pathogenesis,” Neurotoxicity Research, vol. 16, no. 3, pp. 271–279, 2009. View at Publisher · View at Google Scholar · View at PubMed
  55. M. Gerlach, P. Riederer, and K. L. Double, “Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 14, supplement 2, pp. S185–S188, 2008. View at Publisher · View at Google Scholar · View at PubMed
  56. H. Wilms, L. Zecca, P. Rosenstiel, J. Sievers, G. Deuschl, and R. Lucius, “Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications,” Current Pharmaceutical Design, vol. 13, no. 18, pp. 1925–1928, 2007. View at Publisher · View at Google Scholar
  57. L. Zecca, H. Wilms, S. Geick et al., “Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease,” Acta Neuropathologica, vol. 116, no. 1, pp. 47–55, 2008. View at Publisher · View at Google Scholar · View at PubMed
  58. M. G. Tansey and M. S. Goldberg, “Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention,” Neurobiology of Disease, vol. 37, no. 3, pp. 510–518, 2010. View at Publisher · View at Google Scholar · View at PubMed
  59. W. Zhang, K. Phillips, A. R. Wielgus et al., “Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease,” Neurotoxicity Research, vol. 19, no. 1, pp. 63–72, 2011. View at Publisher · View at Google Scholar · View at PubMed